Company intelligence / Profile preview
Endevica Bio
Northbrook, Illinois, United Statesendevicabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Endevica Bio develops first-in-class peptide therapeutics using proprietary peptidomimetic technology. Its lead candidate, TCMCB07, a melanocortin receptor antagonist peptide, has shown positive safety results in Phase 1 trials and will enter a pivotal Phase 2 trial in patients with stage IV metastatic colorectal cancer to prevent chemotherapy-induced weight loss. The company also has preclinical programs targeting obesity and metabolic disorders with promising animal efficacy data showing weight loss without typical GLP‑1 side effects. The technology enables modulation of key CNS drug targets by crossing the blood-brain barrier safely and effectively.
- Therapeutic areas
- OncologyMetabolic Disorders
- Modalities
- Peptide therapeutics (peptidomimetics)Synthetic peptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Endevica Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endevica Bio.